Physician profile
Robert S Greenbaum
NPI 1750387973
$1,839.42
in general payments reported to CMS, 2019-2025
11 companies · $630 in 2025
The $630 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $204 · 2021: $69.26 · 2022: $116 · 2023: $426 · 2024: $199 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $776.95 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Coopervision INC. | $271.71 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.00 | 2019-2020 | |
| Allergan, INC. | $157.06 | 2020-2021 | |
| Horizon Therapeutics Plc | $124.38 | 2023 | Tepezza |
| Dompe US, INC. | $100.00 | 2023 | Oxervate |
| Optos, INC. | $79.41 | 2022 | |
| Visioneering Technologies, INC. | $59.34 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $52.57 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $35.33 | 2024-2025 | |
| Alcon Vision LLC | $22.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.